Single drug · single cancer type

Deep-dive analysis focused on one drug-indication pair across all five cancer groups in our dataset.

Response enrichment & responder population

Quantified enrichment score and estimated responder population size within the target indication.

Responder Architecture Map

Full geometric map of drug response across the patient population — nodes, clusters, and subgroup structure visualised.

Subgroup classification & biomarker associations

Molecular characterisation of the responder subgroup including gene expression signatures and somatic mutation enrichment.

Cross-drug comparison

Architecture benchmarked against comparable drugs in the same indication — contextualising your drug's responder geometry.

Clinical translation & trial design implications

Sample size calculation for an enriched trial design — including projected reduction versus an all-comers approach.

Next steps & recommendations

Actionable guidance on how to use the architecture findings for biomarker development, trial enrichment, or further validation.